Despite the results highlighted in this text, we eagerly await data from the various phase II clinical trials, as described above, but also from the one investigating CBD for the treatment of aromatase inhibitor-associated arthralgias (ClinicalTrials.gov Identifier: NCT04754399). Here, CYP19A1 is linked to Arthralgia.